Pentavalent rotavirus vaccine (RotaTeq®): A review of its use in the prevention of rotavirus gastroenteritis in Europe

Drugs

Volumn 70, Issue 9, 2010, Pages 1165-1188

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Rotavirus infections; Rotavirus W179 9 vaccine, general

Indexed keywords

ROTAVIRUS VACCINE;

ABSENTEEISM; ACTIVE IMMUNIZATION; AUSTRALIA; CAREGIVER; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY WARD; EUROPE; FEVER; HEALTH PROGRAM; HEMATOCHEZIA; HERD IMMUNITY; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; INTUSSUSCEPTION; IRRITABILITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PARENT; POSTMARKETING SURVEILLANCE; RASH; REVIEW; RHINOPHARYNGITIS; ROTAVIRUS; SEROTYPE; SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; EUROPE; FEMALE; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; IMMUNIZATION SCHEDULE; INFANT; INTUSSUSCEPTION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; VACCINES, ATTENUATED;

BOVINAE; ROTAVIRUS;

EID: 77953118222     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205030-000000000-00000     Document Type: Review

References (111)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9 (5): 565-572
2. Leung AK, Kellner JD, Davies HD. Rotavirus gastroen-teritis. Adv Ther 2005; 22 (5): 476-487
3. Cortese MM, Parashar UD. Prevention of rotavirus gastro-enteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009 Feb 6; 58 (RR-2): 1-25
4. Giaquinto C, Damme PV. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. Scand J Infect Dis 2010; 42 (2): 142-147
5. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004 Aug; 33 (8): 536-543
6. Parashar UD, Alexander JP, Glass RI. Prevention of rota-virus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 Aug 11; 55 (RR-12): 1-13
7. Gray J, Vesikari T, Van Damme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S24-31
8. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl. 1: S4-16
9. Monto AS. Epidemiology of influenza. Vaccine 2008 Sep 12; 26 Suppl. 4: D45-8
10. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity: United States, July 2007-December 2008. MMWR Morb Mortal Wkly Rep 2008 Dec 19 57, 50, 1355-1358.
11. Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304-306
12. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Bur-den of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006 Jan; 25 (1 Suppl.): S7-11
13. Giaquinto C, Van Damme P, Huet F, et al. Clinical con-sequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl. 1: S26-35
14. Armengaud J-B, El Hajje MJ, Moulin F, et al. Simulta-neous outbreaks of rotavirus and respiratory syncitial virus in Paris: a 12-year survey [in French]. Med Mal Infect 2007; 37: 262-265
15. Maille L, Beby-Defaux A, Bourgoing A, et al. Nosocomial infections due to rotavirus and respiratory syncytial virus in pediatric wards: a 2-year study [in French]. Ann Biol Clin (Paris) 2000; 58: 601-606
16. Gleizes O, Desselberger U, Tatochenko V, et al. Nosoco-mial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-aquired rotavirus disease. Pediatr Infect Dis J 2006 Jan; 25 (1 Suppl.): S12-21
17. Cunliffe NA, Booth JA, Elliot C, et al. Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis 2010 Jan; 16 (1): 55-62
18. Giaquinto C, Van Damme P, Huet F, et al. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007 May 1; 195 Suppl. 1: S36-44
19. Van Der Wielen M, Da Dalt L, Giaquinto C, et al. Impact of paediatric acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) on family life: the REVEAL study [abstract]. 25th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2007 May 2-4; Porto
20. Mast TC, DeMuro-Mercon C, Kelly CM, et al. The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009; 9: 11
21. O'Ryan M. The ever-changing landscape of rotavirus sero-types. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S60-2
22. Dennehy PH. Rotavirus vaccines: an update. Vaccine 2007 Apr 20; 25 (16): 3137-3141
23. Dennehy PH. Rotavirus vaccines: success after failure. Med Health R I 2007 Oct; 90 (10): 321-324
24. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29-56
25. Van Damme P, Giaquinto C, Maxwell M, et al. Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study. J Infect Dis 2007 May 1; 195 Suppl. 1: S17-25
26. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983 Jul 14; 309 (2): 72-76
27. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rota-virus diarrhea. J Infect Dis 1993 Aug; 168 (2): 282-287
28. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996 Oct 3; 335 (14): 1022-1028
29. Velazquez FR. Protective effects of natural rotavirus in-fection. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S54-6
30. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38-48
31. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 615-618
32. American Academy of Pediatrics. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics. 2009 May, 123, 5, 1412-1420.
33. World Health Organization. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; (32): 325-332
34. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004 May 8; 363 (9420): 1547-1550
35. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008 Jan; 21 (1): 198-208
36. RotaTeq® (rotavirus vaccine): US prescribing information. Whitehouse Station (NJ): Merck & Co., Inc. 2009 Feb
37. RotaTeq® (rotavirus vaccine): EU summary of product characteristics. Lyon, France: Sanofi Pasteur MSD, SNC. 2006 Jun 27
38. Keating GM. Rotavirus vaccine (RotaTeq®). Paediatr Drugs 2006; 8 (3): 197-202; discussion 203-204
39. Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005 Sep 1; 192 Suppl. 1: S17-21
40. Vesikari T, Matson DO, Dennehy P, et al. Safety and effi-cacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006 Jan 5; 354 (1): 23-33
41. Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009 Mar; 28 (3): 177-181
42. Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008 Oct; 27 (10): 874-880
43. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007 Mar; 26 (3): 221-227
44. Vesikari T, Karvonen A, Kitchin N, et al. Co-administra-tion of pentavalent rotavirus vaccine, RotaTeq®, with meningococcal group C conjugate vaccine: immunogeni-city and safety [abstract plus poster]. 2nd Congress of the European Academy of Paediatrics; 2008 Oct 24-28; Nice
45. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immu-nogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007 Jan; 119 (1): 11-18
46. Chang CC, Chang MH, Lin TY, et al. Experience of pen-tavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. J Formos Med Assoc 2009 Apr; 108 (4): 280-285
47. Kim DS, Lee TJ, Kang JH, et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008 Feb; 27 (2): 177-178
48. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq®, a pen-tavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2010; 28 (2): 345-351
49. Vesikari T, Karvonen A, Allen S, et al. Serotype-specific efficacy of the pentavalent rotavirus vaccine against hospitalizations and emergency department visits up to three years: the Finnish Extension Study [abstract no. G2-3747]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
50. Vesikari T, Karvonen A, Allen S, et al. Efficacy of penta-valent rotavirus vaccine, RotaTeq®, against hospitalizations and emergency department visits through the third year: the Finnish Extension Study [abstract no. 19.025]. 13th International Congress on Infectious Diseases; 2008 Jun 19-22; Kuala Lumpur
51. Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine between doses: potential benefits of early protection [abstract no. 5628.7]. 2008 Annual Meeting of the Pediatric Academic Societies LateBreakers; 2008 May 2-6; Honolulu (HI)
52. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pen-tavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007 Nov; 11 Suppl. 2: S29-35
53. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007 Dec; 26 (12): 1099-1104
54. Van der Wielen M, Van Damme P. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. Eur J Clin Microbiol Infect Dis 2008 Jul; 27 (7): 495-501
55. Goveia MG, DiNubile MJ, Dallas MJ, et al. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008 Jul; 27 (7): 656-658
56. Newman RD, Grupp-Phelan J, Shay DK, et al. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999 Jan; 103 (1): e3 Data on file, Sanofi Pasteur, Lyon, France, 2010
57. Vesikari T, Karvonen A, Ferrante SA, et al. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. Epub 2010 May 3
58. Reduction in rotavirus after vaccine introduction: United States 2000-2009. MMWR Morb Mortal Wkly Rep 2009 Oct 23, 58, 41, 1146-1149
59. Delayed onset and diminished magnitude of rotavirus ac-tivity: United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep. 2008, Jun 27, 57, 25, 697-700
60. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009 Aug; 124 (2): 465-471
61. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010 Feb; 125 (2): e208-13
62. Lieberman JM, Huang X, Koski E, et al. Decline in rotavirus cases in the U.S. after licensure of a live, oral rotavirus vaccine [abstract no. G1-437]. 48th Annual In-terscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
63. Parashar U, Panozzo C, Bartlett D, et al. Monitoring the uptake and impact of the new U.S. rotavirus vaccination program [abstract no. G2-3748]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
64. Cortese M, Tate J, Simonsen L, et al. Reduction in gas-troenteritis in children and correlation with rotavirus vaccine uptake from a medical claims database [abstract no. 1153]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
65. Cortes J, Curns A, Tate J, et al. Impact and effectiveness of rotavirus vaccine on diarrhea-associated healthcare utilization in US children [abstract no. LB-35]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
66. Chang HG, Smith PF, Tserenpuntsag B, et al. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010; 28: 754-758
67. Clark HF, Lawley D, Mallette LA, et al. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentava-lent rotavirus vaccine. Clin Vaccine Immunol 2009 Mar; 16 (3): 382-386
68. Boom J, Tate J, Sahni L, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010 Feb; 125 (2): e199-207
69. Anderson EJ, Rupp A, Stulman ST, et al. Impact of vaccina-tion upon nosocomial acquisition of rotavirus [abstract no. 1149]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
70. Begue RE, Perrin K. Efficiency of pentavalent rotavirus vaccine in primary practice [abstract no. 2755.8]. Annual Meeting of the Pediatric Academic Societies; 2009 May 2-5; Baltimore (MD)
71. Custodio H, Halstead D, Maraqa N, et al. Decrease in rotavirus infection and hospitalization in Northeast Florida after the introduction of rotavirus vaccine [abstract no. 5515.305]. Annual Meeting of the Pediatric Academic Societies; 2009 May 2-5; Baltimore (MD)
72. Harrison CJ, Jackson M, Olson-Burgess C, et al. Fewer 2008 hospitalizations for rotavirus (RV) in Kansas City, two years post RV vaccine [abstract no. G1-435]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
73. Payne DC, Edwards KM, Staat MA, et al. Decline in rota-virus hospitalizations in 3 US counties after introduction of rotavirus vaccine [abstract no. 3400.3]. Annual Meeting of the Pediatric Academic Societies; 2009 May 2-5; Baltimore (MD)
74. Patel JA, Loeffelholz M. Reduction of severe rotavirus gastroenteritis following the routine use of live, oral, pentavalent rotavirus vaccine [abstract no. G1-434]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
75. Desai SN, Shapiro ED, Dennehy PH, et al. Effectiveness of rotavirus vaccine in preventing hospitalization of young children [abstract no. 1152]. 47th Annual Meeting of the Infectious Diseases Association of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
76. Daskalaki I, Wood SJ, Inumerable Y, et al. No further reduction in rotavirus-associated hospitalizations in north Philadelphia after universal immunization of a second birth cohort [abstract no. 1154]. 47th Annual Meeting of the Infectious Diseases Association of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
77. Herrera Guerra AA, Pavia AT, Thorell EA, et al. Impact of rotavirus vaccination in two Utah hospitals [abstract no. 1150]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
78. Hatch S, Fontecchio S, Gibson L, et al. Rapid decline in pediatric rotavirus cases following introduction of rotavirus vaccine [abstract no. G1-436]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
79. Lambert SB, Faux CE, Hall L,et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009 Aug 3; 191 (3): 157-160
80. Gagneur A, Lemaitre T, Nowak E, et al. Impact of a VAccination campaign in infants (Nourrissons) on HOs-pitalisations for acute rotavirus gastro-Enteritis: prospective study in the Brest Urban Community, in France. IVANHOE study [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
81. GlaxoSmithKline. FDA approves Rotarix [rotavirus vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age [online]. Available from URL:
82. Raes M, Strens D, Vergison A, et al. Second year post-rotavirus vaccination in Belgium: impact on rotavirus-positive stool samples in hospitalized children [abstract]. 28th Annual Meeting of the European Society for Pae-diatric Infectious Diseases; 2010 May 4-8; Nice
83. Matthijnssens J, Rahman M, Zeller M, et al. Rotavirus incidence and genotype fluctuations in the Gasthuisberg University Hospital three years after national rotavirus vaccine introduction in Belgium [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
84. Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera MDM, et al. Rotavirus vaccination effectiveness in Cas-tellon (Spain): preliminary results using data from a specific diarrhoea study and the regional vaccine registry [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
85. Martinon-Torres F, Bouzon-Alejandro M, Pertega Diaz S, et al. Prospective estimation of rotavirus vaccine effectiveness in Spain [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
86. Rodrigues F, Iturriza M, Gonclaves G, et al. Large varia-tions in rotavirus (RV) disease and strain diversity during low-level vaccine use in Portugal [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
87. Dennehy PH, Goveia MG, Dallas MJ, et al. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007 Nov; 11 Suppl. 2: S36-42
88. Haber P, Patel M, Izurieta HS, et al. Postlicensure mon-itoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008 Jun; 121 (6): 1206-1212
89. Postmarketing monitoring of intussusception after Rota-Teq vaccination: United States, February 1, 2006-Feb-ruary 15, 2007. MMWR Morb Mortal Wkly Rep 2007 Mar 16, 56, 10, 218-222
90. Belongia EA, Irving SA, Shui IM, et al. Real-time surveil-lance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010; 29 (1): 1-5
91. Irving SA, Shui IM, Kulldorff M, et al. Rapid cycle ana-lysis of pentavalent rotavirus vaccine safety in the vaccine safety datalink (VSD) population [abstract no. G1-439]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 Oct 25-28; Washington, DC
92. Rotavirus vaccination coverage and adherence to the Ad-visory Committee on Immunization Practices (ACIP)-recommended vaccination schedule: United States, February 2006-May 2007. MMWR Morb Mortal Wkly Rep 2008 Apr 18 57 15 398-401
93. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and 'no medical care' disease impact in Belgium. Med Decis Making 2009 Jan-Feb; 29 (1): 33-50
94. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II: the potential cost-effectiveness of vaccination. Vaccine 2007 May 16; 25 (20): 3971-3979
95. Lorgelly PK, Joshi D, Iturriza Gomara M, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008 Jan; 136 (1): 44-55
96. Nohynek H, Salo H, Renko M, et al. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009; 14 (35): 1-3
97. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008 Jan 30; 26 (5): 706-715
98. Giammanco MD, Coniglio MA, Pignato S, et al. An eco-nomic analysis of rotavirus vaccination in Italy. Vaccine 2009 Jun 8; 27 (28): 3904-3911
99. Mangen MJJ, van Duynhoven YTHP, Vennema H, et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010; 28: 2624-2635
100. Zomer TP, van Duynhoven YT, Mangen MJ, et al. Asses-sing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008 Jul 4; 26 (29-30): 3757-3764
101. Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009 Oct 19; 27 (44): 6121-6128
102. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 Jul 28; 163: 1637-1641
103. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001 Dec 1; 323: 1300-1303
104. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
105. Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5): 518-528
106. Vesikari T, Sutherland D, Jackson AEM. Report of the 'European Expert Meeting on Rotavirus Vaccination', Tampere, Finland, 19-20 May 2009. Vaccine 2009; 27:7222-7227
107. Kempe A, Patel MM, Daley MF, et al. Adoption of rotavirus vaccination by pediatricians and family medicine physicians in the United States. Pediatrics 2009 Nov; 124 (5): e809-16
108. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of hu-man rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007 Nov 24; 370: 1757-1763
109. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan 5; 354 (1): 11-22
110. Rotarix® (rotavirus vaccine): EU summary of product characteristics. Rixensart, Belgium; GlaxoSmithKline Biologicals s.a. 2006 Feb 21
111. Iturriza-Gomara M, Dallman T, Banyai K, et al. Rotavirus surveillance in Europe, 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological data. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S215-21